Researchers in Miami and San Francisco will be testing the effectiveness of pre-exposure prophylaxis (PrEP) to prevent HIV in a pilot study funded by the National Institutes of Health, The New York Times reports. The study will recruit up to 500 uninfected men who have sex with men who are considered to be at high risk. Participants will be asked to take the antiretroviral drug Truvada daily. Researchers will track their sexual behavior and HIV status. Advocates are raising questions about whether healthy people will take an expensive drug that can cause side effects, whether it's fair to provide meds to HIV-negative individuals when some HIV-positive people struggle for access, and whether those taking the drug will be more likely to engage in risky behavior because they believe they're protected from HIV.

To read the Times article, click here.